Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide.

Détails

ID Serval
serval:BIB_86A4D2150D3A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide.
Périodique
Cancer Science
Auteur(s)
Borbath I., Leclercq I.A., Abarca-Quinones J., Desaeger C., Lebrun V., Moulin P., Sempoux C., Horsmans Y.
ISSN
1349-7006 (Electronic)
ISSN-L
1347-9032
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
98
Numéro
12
Pages
1831-1839
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death, and its incidence is increasing worldwide. Due to the known risk factors (mainly hepatitis B and C viruses), we believe there is a rationale for a chemopreventive approach to treat HCC. Here, based on described in vitro data, we evaluated the preventive effects of lanreotide, a somatostatin analog, on the induction of early carcinogenic events. We monitored preneoplastic foci induced by a two-stage initiation/promotion model of hepatocarcinogenesis in male Wistar rats, using diethylnitrosamine and 2-acetylaminofluorene. Lanreotide was given starting the day after the first diethylnitrosamine injection. By quantitative morphometry, we showed that lanreotide significantly decreases the size of induced preneoplastic foci. Analysis of proliferation and apoptosis assessed by immunohistochemistry, showed decreased proliferation and increased cell death in rats treated with lanreotide. As these events were associated with a significant decreased expression of the cell cycle regulator cyclin D1 and an increased expression of the cyclin-dependent kinase inhibitor p27(kip1) compared to the non-treated group, it is tempting to speculate that these factors are involved in the favorable effect of lanreotide. In conclusion, lanreotide significantly decreases early carcinogenic transformation in a two-step rat model. As lanreotide has a low toxicity profile, we believe it would be interesting to evaluate its effect in chemoprevention of HCC.
Mots-clé
Animals, Antineoplastic Agents/therapeutic use, Carcinoma, Hepatocellular/chemically induced, Carcinoma, Hepatocellular/pathology, Cell Division, Diethylnitrosamine/toxicity, Liver Neoplasms/chemically induced, Liver Neoplasms/pathology, Male, Peptides, Cyclic/therapeutic use, Polymerase Chain Reaction, Precancerous Conditions/pathology, Precancerous Conditions/prevention & control, RNA, Neoplasm/genetics, RNA, Neoplasm/isolation & purification, Rats, Rats, Wistar, Somatostatin/analogs & derivatives, Somatostatin/therapeutic use
Pubmed
Web of science
Création de la notice
20/10/2016 17:09
Dernière modification de la notice
03/03/2018 18:59
Données d'usage